|Target||TGF beta 1|
|(what is this?)|
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future, metelimumab was dropped from further development in favour of fresolimumab, which is currently being developed by Genzyme.
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.
Initial trials targeted the skin condition scleroderma but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab, which is currently being developed by Genzyme.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|